preview

Zyn001 Case Summary

Satisfactory Essays

Size of the market for the product ZYN001 is developed to treat patients with fibromyalgia and peripheral neuropathy pain. Since fibromyalgia is estimated to affect about 10 million people in the United States and 20 million people are estimated to have some forms of peripheral neuropathic pain, the maximum of the market size of ZYN001 can be 30 million people. ZYN002 aims to treat patients with epilepsy, osteoarthritis and fragile X syndrome. Consider that patient with active epilepsy count up to 3 million in the United State, an estimated 27 million for osteoarthritis and about 1.3 million for fragile X syndrome, the estimated market size of ZYN002 is up to 31.3 million patients. So the total market size of Zynerba is about 61.3 million

Get Access